Texas is currently home to 5031 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
Recruiting
To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6
Gender:
Female
Ages:
Between 25 years and 70 years
Trial Updated:
04/19/2022
Locations: Austin Area Obstetrics, Gynecology, and Fertility, Austin, Texas
Conditions: ASC-US, ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial Lesion, LSIL
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Recruiting
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic). Larotrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
16 years and above
Trial Updated:
04/18/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Creating Physical Objects With 3D Printers to Stimulate Reminiscing for Memory Loss [2 R44 AG049548-02A1]
Recruiting
In 2013 an estimated 5 million people age 65 and older had Alzheimer's disease. Longer life spans and aging baby boomers will cause this number to grow rapidly. More than 50% of residents in assisted living and nursing homes have some form of dementia or cognitive impairment and the number is increasing every day. As a form of person-centered, non-pharmacological dementia care, Reminiscence Therapy (RT) holds considerable promise. Improvements in mood, quality of life, social interaction, cogni... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2022
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Dementia
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Recruiting
The aim of this study is to evaluate the feasibility of a digital health coaching program for, and to describe quality of life of, individuals in the 6 months following chimeric antigen receptor (CAR) T cell therapy. Up to 50 English-speaking individuals aged 18 and older who are to receive treatment with a CAR T cell therapy will be enrolled, all at The University of Texas MD Anderson Cancer Center. Participants must have internet access via smart phone, tablet, a computer, or another device wi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2022
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, Lymphoma, B-Cell, Leukemia, Multiple Myeloma, Mantle Cell Lymphoma, Follicular Lymphoma, Leukemia, Acute Lymphoblastic
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
Recruiting
RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in patients with locally advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2022
Locations: University of Texas at MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Reducing Mental Health in Informal Caregivers
Recruiting
The overarching goal of this project is to evaluate if evidence-based interventions can reduce PDG, burden, and stress in informal caregivers of individuals with dementia
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/11/2022
Locations: Texas Tech University, Lubbock, Texas
Conditions: Mental Health Issue, Grief, Burden, Caregiver
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
Recruiting
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress syndrome.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2022
Locations: PRX Research/Dallas Regional Medical Center, Mesquite, Texas
Conditions: Covid19
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
Recruiting
The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application f... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/05/2022
Locations: John Peter Smith Hospital, Fort Worth, Texas
Conditions: Fungal Infection, Onychomycosis, Tinea Unguium
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Baylor College of Medicine, Houston, Texas
Conditions: End Stage Liver Disease
Development of Protocols and Methods for Image Processing and Enhancement of Magnetic Resonance Imaging (MRI) Data.
Recruiting
The purpose of the study is to develop new methods for image processing and enhancement of MRI data. Different setting of acquisition parameters used in conventional clinical MRI protocols will be defined, to create "New Protocols". The specific aim of this study is to assess and to improve the performance of our image processing methods, by comparing diagnostic qualities of images obtained by conventional MRI protocols with those obtained by corresponding New Protocols' and processed by our im... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: Houston Medical Imaging, Houston, Texas
Conditions: MRI Image Enhancement
Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
Recruiting
The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
Gender:
All
Ages:
Between 10 minutes and 7 days
Trial Updated:
03/31/2022
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Congenital Diaphragmatic Hernia
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: East Texas Cardiology, Houston, Texas
Conditions: Heart Failure, Reduced Ejection Fraction